Trial Profile
Weekly Subcutaneous Bortezomib Is Well Tolerated and Effective As Initial Therapy Of Symptomatic Myeloma
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 20 Aug 2014
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Cyclophosphamide; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- 20 Aug 2014 New trial record